Internal Medicine, Infectious Disease · Myrtle Beach, SC
NPI
1376593673
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1110 London St Ste 102
Myrtle Beach, SC, 29577
Phone (843) 668-2376
Groups this clinician bills Medicare through
Medicare paid, 2024
$303K
3,849 services
Medicare patients, 2024
481
Average age 75
Drug cost, 2024
$1.1M
1,887 prescriptions
Company payments, 2023
$72.35
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Yama Osmanzai was code 99232 (hospital e&m - subsequent), 2,413 times for 321 patients. In total Yama Osmanzai billed 3,849 services in 7 codes, and Medicare paid $303K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-12-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 2,413 | 321 | $58.42 | $141K |
| 99223 Hospital E&M - Initial | Facility | 432 | 340 | $126.07 | $54K |
| 99233 Hospital E&M - Subsequent | Facility | 404 | 315 | $88.07 | $36K |
| 99215 Office E&M - Established | Office | 295 | 172 | $125.71 | $37K |
| 99214 Office E&M - Established | Office | 168 | 86 | $89.47 | $15K |
| 99291 Critical Care E&M | Facility | 99 | 44 | $156.89 | $16K |
| 99204 Office E&M - New | Office | 38 | 38 | $118.83 | $4,515 |
By year: 2022 $379K for 4,760 services; 2023 $351K for 4,501 services; 2024 $303K for 3,849 services.
Medicare prescription drug claims, 2024
In 2024, the drug Yama Osmanzai prescribed most often to Medicare patients was Daptomycin, with 175 prescriptions and refills. In total Yama Osmanzai wrote 1,887 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Daptomycin Generic | 175 | 175 | 40 | $250K |
| Meropenem Generic | 144 | 144 | 32 | $40K |
| Ceftriaxone Ceftriaxone Sodium | 138 | 138 | 38 | $15K |
| Vancomycin Hcl Generic | 120 | 120 | 29 | $29K |
| Doxycycline Hyclate Generic | 105 | 128 | 26 | $2,136 |
| Cefepime Hcl Generic | 102 | 102 | 23 | $34K |
| Cefazolin Sodium Generic | 90 | 90 | 16 | $3,526 |
| Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam | 72 | 72 | 21 | $19K |
| Cephalexin Generic | 63 | 71 | Under 11 | $959 |
| Levofloxacin Generic | 62 | 64 | 22 | $440 |
| Ampicillin-Sulbactam Ampicillin Sod/Sulbactam Sod | 59 | 59 | Under 11 | $7,774 |
| Azithromycin Generic | 49 | 64 | Under 11 | $1,233 |
| Dovato Dolutegravir Sodium/Lamivudine | 47 | 47 | Under 11 | $141K |
| Ertapenem Ertapenem Sodium | 46 | 46 | 18 | $28K |
| Ethambutol Hcl Generic | 44 | 50 | Under 11 | $2,945 |
Brand drugs: 248 claims; generic drugs: 1,639 claims.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Yama Osmanzai $72.35 ($72.35 in general payments such as food, travel and fees) from 1 company. The largest payer was Insmed, Inc. with $72.35.
| Company | Payments | Amount |
|---|---|---|
| Insmed, Inc. INSM | 1 | $72.35 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.